Vivoryon
1 known investors
Vivoryon develops small molecule medicines targeting inflammatory and fibrotic kidney disorders, with a lead program (varoglutamstat) designed to treat diabetic kidney disease through protein modulation.
1 known investors
Vivoryon develops small molecule medicines targeting inflammatory and fibrotic kidney disorders, with a lead program (varoglutamstat) designed to treat diabetic kidney disease through protein modulation.